Comparative Pharmacology
Head-to-head clinical analysis: PULMICORT RESPULES versus QVAR 80.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PULMICORT RESPULES versus QVAR 80.
PULMICORT RESPULES vs QVAR 80
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucocorticoid receptor agonist; anti-inflammatory; decreases cytokine production, inhibits inflammatory cell migration, and reduces airway hyperresponsiveness.
Beclomethasone dipropionate is a corticosteroid that exhibits anti-inflammatory activity. It binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators such as cytokines, chemokines, and arachidonic acid metabolites. It also reduces edema and mucus production in the airways.
0.5 mg to 1 mg twice daily via nebulization; for maintenance or as replacement therapy, initiate at 0.25 mg twice daily and titrate to clinical response.
80 mcg orally via oral inhalation twice daily (maximum 320 mcg twice daily)
None Documented
None Documented
Terminal half-life approximately 2-3 hours in children and adults; slightly prolonged in hepatic impairment. Clinical context: supports twice-daily dosing in asthma.
Terminal elimination half-life is approximately 2.9 hours after inhalation. This short half-life supports twice-daily dosing but does not fully reflect pulmonary residence time.
Renal: negligible (<5% as unchanged drug). Biliary/fecal: major route, approximately 60-70% as metabolites. Total clearance: 0.5-1.0 L/h.
Primarily hepatic metabolism, with metabolites excreted in feces (60-70%) and urine (30-40%). Less than 1% of unchanged drug is excreted in urine.
Category C
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid